Innate Pharma - IPHA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.75
  • Forecasted Upside: 236.06%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.90
▼ -0.06 (-2.03%)

This chart shows the closing price for IPHA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Innate Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPHA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPHA

Analyst Price Target is $9.75
▲ +236.06% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Innate Pharma in the last 3 months. The average price target is $9.75, with a high forecast of $11.50 and a low forecast of $8.00. The average price target represents a 236.06% upside from the last price of $2.90.

This chart shows the closing price for IPHA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Innate Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.50Low
4/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.50Low
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.50Low
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.50Low
9/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.50Low
9/18/2023CitigroupLower Target$12.00 ➝ $8.00Low
4/10/2023SVB SecuritiesBoost Target$9.00 ➝ $10.00Low
3/24/2023HC WainwrightReiterated RatingBuy$11.50Low
11/15/2022SVB LeerinkLower TargetOutperform$10.00 ➝ $9.00Low
9/16/2022CitigroupLower TargetBuy$16.00 ➝ $12.00Low
8/3/2022Kepler Capital MarketsDowngradeBuy ➝ Hold€3.10Low
8/2/2022SVB LeerinkLower TargetOutperform$11.00 ➝ $10.00Low
3/25/2022HC WainwrightReiterated RatingBuy$11.50Low
12/12/2021SVB LeerinkReiterated RatingBuyHigh
9/22/2021CitigroupBoost TargetBuy$7.00 ➝ $14.00Low
9/17/2021Evercore ISIBoost TargetOutperform$6.00 ➝ $10.00High
9/17/2021SVB LeerinkBoost TargetOutperform$7.00 ➝ $9.00High
9/16/2021HC WainwrightReiterated RatingBuy$11.50Low
9/2/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$7.00High
3/19/2021SVB LeerinkBoost TargetMarket Perform$5.00 ➝ $7.00Medium
2/4/2021HC WainwrightReiterated RatingBuy$13.00Low
12/15/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$7.00 ➝ $5.00Low
12/14/2020HC WainwrightLower TargetBuy$13.00 ➝ $11.50Low
11/23/2020The Goldman Sachs GroupInitiated CoverageNeutral$4.75High
10/9/2020HC WainwrightReiterated RatingBuy$13.00High
9/9/2020Bryan, Garnier & CoDowngradeBuy ➝ NeutralLow
9/9/2020SVB LeerinkLower TargetOutperform$9.00 ➝ $7.00High
5/14/2020SVB LeerinkLower TargetOutperform$10.00 ➝ $9.00Low
11/26/2019HC WainwrightReiterated RatingBuyHigh
11/11/2019SVB LeerinkReiterated RatingOutperformMedium
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/28/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Innate Pharma logo
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Read More

Today's Range

Now: $2.90
Low: $2.90
High: $3.00

50 Day Range

MA: $2.55
Low: $2.28
High: $3.00

52 Week Range

Now: $2.90
Low: $1.81
High: $3.57

Volume

17,324 shs

Average Volume

6,617 shs

Market Capitalization

$234.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Innate Pharma?

The following Wall Street analysts have issued reports on Innate Pharma in the last twelve months: Citigroup Inc., and HC Wainwright.
View the latest analyst ratings for IPHA.

What is the current price target for Innate Pharma?

2 Wall Street analysts have set twelve-month price targets for Innate Pharma in the last year. Their average twelve-month price target is $9.75, suggesting a possible upside of 236.1%. HC Wainwright has the highest price target set, predicting IPHA will reach $11.50 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $8.00 for Innate Pharma in the next year.
View the latest price targets for IPHA.

What is the current consensus analyst rating for Innate Pharma?

Innate Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IPHA will outperform the market and that investors should add to their positions of Innate Pharma.
View the latest ratings for IPHA.

What other companies compete with Innate Pharma?

How do I contact Innate Pharma's investor relations team?

Innate Pharma's physical mailing address is 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009. The company's listed phone number is 33-4-30-30-30-30 and its investor relations email address is [email protected]. The official website for Innate Pharma is www.innate-pharma.com. Learn More about contacing Innate Pharma investor relations.